SCHEMBL19290000

SCHEMBL19290000

CCC(CC)NC(Cc1ccccc1)C(C)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 2/20 0.48
▸ HDAC4 P56524 2/20 0.48
▸ HDAC1 Q13547 2/20 0.48
▸ HDAC2 Q92769 2/20 0.48
▸ HDAC8 Q9BY41 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ MME P08473 2/20 0.47
▸ ACE P12821 2/20 0.47
▸ CPA1 P15085 2/20 0.47
▸ ACE2 Q9BYF1 2/20 0.47
▸ LMNA P02545 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CTSS P25774 1/20 0.46
▸ CTSK P43235 1/20 0.46
▸ PAM P19021 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ALPI P09923 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ PTGS1 P23219 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24084101 0.85 TRPA1 (0.49) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL16252309 0.83 LMNA (0.53) ALDH1A1MMEACECPA1ACE2
SCHEMBL13233695 0.83 LMNA (0.53) ALDH1A1MMEACECPA1ACE2
SCHEMBL19088387 0.83 MMP8 (0.55) —
SCHEMBL20427447 0.82 MMP2 (0.52) —
SCHEMBL19088391 0.80 POLB (0.48) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL14027140 0.79 SIGMAR1 (0.55) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL19088526 0.79 TSHR (0.48) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL17793545 0.79 ALDH1A1 (0.51) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL8175870 0.79 TAAR1 (0.52) ALDH1A1MMECTSSCTSKPAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861581-B9 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. BRISTOL MYERS SQUIBB CO (US) 2017-08-30 — — EP disclosed
Send feedback